Point-of-Care International Normalized Ratio (INR) Testing Market Report 2026

The point-of-care inr testing market size has grown rapidly in recent years. It will grow from $1.58 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, growing use of anticoagulant therapy, rising incidence of atrial fibrillation, expansion of outpatient and homecare settings, increasing need for rapid coagulation testing.

The point-of-care inr testing market size is expected to see rapid growth in the next few years. It will grow to $2.56 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for home-based monitoring, growing geriatric population on long-term anticoagulation, rising focus on personalized anticoagulation management, expansion of decentralized healthcare models, increasing adoption in primary care clinics. Major trends in the forecast period include technological advancements in portable coagulation analyzers, innovations in biosensor and microfluidic technologies, developments in wireless connectivity and data integration, research and development in high-accuracy test strips, advancements in smartphone-enabled inr testing.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the point-of-care International Normalized Ratio (INR) testing market in the coming years. Cardiovascular diseases are conditions affecting the heart and blood vessels, including heart attacks, strokes, and hypertension, and are rising due to unhealthy lifestyles such as poor diet, lack of exercise, and smoking. Point-of-care INR testing supports cardiovascular disease management by enabling rapid assessment of blood coagulation status at the bedside or clinic. It enhances clinical decision-making by allowing timely detection of clotting abnormalities and guiding anticoagulation therapy. For example, in October 2024, the Centers for Disease Control, a US-based government agency, reported that in 2023, approximately 919,032 people died from cardiovascular disease, representing 1 in every 3 deaths. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the point-of-care INR testing market.

Major companies in the point-of-care International Normalized Ratio (INR) testing market are focusing on developing advanced products, such as patient self-monitoring coagulation analyzers, to expand decentralized testing and shift recurring demand toward lower-cost consumables. Patient self-monitoring coagulation analyzers are portable devices that allow patients to perform PT/INR testing at home using a small capillary blood sample, enabling frequent monitoring while reducing reliance on clinical visits. For example, in March 2024, Universal Biosensors, an Australia-based medical device company, launched the Xprecia Prime 4U Coagulation Analyzer for patient self-monitoring. This handheld analyzer provides rapid PT/INR results from a single drop of capillary blood and utilizes an electrochemical strip format that meets regulatory approvals, including 510(k) clearance and CLIA waiver for the U.S. market. This launch marks a significant advancement in INR testing by broadening access to home monitoring, increasing test frequency, and improving cost efficiency through higher consumable utilization, while maintaining clinical accuracy.

In September 2025, Una Health Ltd., a UK-based medical technology company, partnered with iLine Microsystems Pvt. Ltd. to expand the distribution of International Normalized Ratio (INR) monitoring solutions that simplify anticoagulation management. Through this agreement, Una Health Ltd. and iLine Microsystems aim to improve access to easy-to-use portable INR testing devices for patients on blood-thinning therapies, enabling more frequent self-monitoring and better clinical outcomes. iLine Microsystems Pvt. Ltd. is an India-based manufacturer of diagnostics and point-of-care devices.

Major companies operating in the point-of-care international normalized ratio (inr) testing market are Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company, Hoffmann-La Roche Ltd., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Werfen S.A., HORIBA Ltd., Microvisk Ltd., Randox Laboratories Ltd., Nova Biomedical Corporation, Agappe Diagnostics Ltd., Visby Medical Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, HemoSonics LLC, Human Diagnostics Worldwide GmbH, CoaguSense Inc.

North America was the largest region in the Point-of-Care INR Testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care international normalized ratio (inr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care international normalized ratio (inr) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the point-of-care inr testing market by increasing costs of imported diagnostic sensors, electronic components, microfluidic cartridges, and precision manufacturing equipment. healthcare providers in north america and europe are most affected due to dependence on imported testing devices and consumables, while asia-pacific faces pricing pressure on export-oriented device manufacturing. these tariffs are increasing device acquisition costs and influencing procurement decisions for hospitals and clinics. however, they are also encouraging local device assembly, domestic consumable production, and regional innovation in cost-effective point-of-care diagnostics.

Point-of-care International Normalized Ratio (INR) testing refers to the immediate measurement of the INR using portable devices at or near the patient’s location. It enables rapid evaluation of blood clotting status, allowing timely adjustments to anticoagulant therapy. This approach improves patient safety by delivering quick, accurate results without relying on conventional laboratory testing.

The primary product types of point-of-care international normalized ratio testing solutions are devices, consumables, and software. Devices are portable diagnostic instruments used to rapidly measure coagulation status at or near the patient site to support anticoagulation management. These solutions are based on electrochemical and optical technologies and others, distributed through direct sales, retail pharmacies, online or e-commerce channels, and others, used across hospitals, clinics, home care, diagnostic centers, and others, among end users including healthcare professionals and patients.

The point-of-care International Normalized Ratio (INR) testing market consists of revenues earned by entities by providing services such as calibration services, maintenance services, device repair services, data management services, remote monitoring services, technical support services, and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care inr testing market also includes sales of point-of-care INR testing devices, test strips, lancets, control solutions, replacement batteries, carrying cases, and charging adapters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.